San Francisco, 18 January 2019: The Report Hemoglobinopathies Market Size & Forecast By Type (Alpha Thalassemia, Beta thalassemia,
Sickle Cell Disease, Hb Variants Diseases), By Therapy (Blood Transfusion, Iron
Chelation Therapy, Bone Marrow Transplant, Hydroxyurea), By Diagnosis (Blood
Testing, Genetic Testing, Prenatal Genetic Testing, Pre-implantation Genetic
Diagnosis, Hemoglobin Electrophoresis) And Trend Analysis From 2012 To 2022
Global hemoglobinopathies market is expected to reach over USD 8.82 billion by 2022 according to a new report by Grand View Research Inc. Rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is estimated to be the high impact rendering drivers of the market. According to the WHO, hemoglobin disorders are endemic in over 60% of 229 countries affecting over 70% of births. It is also reported that minimum 5% of the world population are carriers of significant variation.
Prevalence of hemoglobinopathies is high in
low-income countries such as Sub Saharan region and South East Asia. 85% of the
affected population in the U.S. and Europe has ancestral base in these
regions.
Governments are collaborating with local
institutes to undertake awareness programs for curbing the effect of
hemoglobinopathies-related mortality rate. For instance, Thalassemia Data
Collection Project and Registry and Surveillance System for Hemoglobinopathies
(RuSH) projects were started in 2010 by the Centers for Disease Control and
Prevention (CDC).
Low level of hygiene, insufficient
healthcare infrastructure, and lesser awareness levels are some key factors
attributing to increase in base of target population in low-income regions such
as South East Asia, Mediterranean basin, and Africa.
Access Research Report of Hemoglobinopathies
Market@ www.grandviewresearch.com/industry-analysis/hemoglobinopathies-market
Further key findings from the study suggest:
· The market for Sickle Cell Disease (SCD)
was the largest with revenue valued at over USD 2,290.0 million in 2014. Rising
prevalence of hemoglobinopathies and presence of strong product pipeline for
sickle cell anemia such as HQK-1001 and Luspatercept are growth promoting
factors of this market.
· Genetic testing for diagnosis of sickle
cell disorders is expected to witness lucrative growth over the forecast
period. It is estimated to grow at a CAGR of around 7.0%. Increasing awareness
levels among people coupled with government programs such as the National
Sickle Cell Disease Control Program conducted by the WHO in Africa are
anticipated to enhance the usage rates for diagnostic tests pertaining to SCD.
· Hydroxyurea was one of the dominating
segments of the SCD therapy market owing to the presence of the FDA-approved
drugs such as Droxia and Hydrea by Bristol Myers Squib. SCD. Thalassemia market
holds an extensive product portfolio in pipeline and their expected
commercialization is anticipated to drive market growth. For instance, The Ellis
Lab is developing a gene therapy for SCD in collaboration with Dr. Victor
Garcia
· Blood tests including cell blood count and
iron studies are the widely used techniques for diagnosis of thalassemia. On
the other hand, pre-implant genetic testing is estimated to grow at lucrative
growth rate over 8.5% in the next six years owing to rising base of health
conscious population and increasing healthcare expenditure.
· The market for blood transfusion was the
largest with revenues valued at over USD 1,408.0 million in therapeutic segment
owing to, high acceptance level of this treatment option and significant
success rate. It is estimated that around 85% of infants below five years
suffering from thalassemia die due to insufficient blood transfusion.
· North America dominated the overall
hemoglobinopathies market in terms of revenue in 2014 at over USD 1,212.0
million. Growing prevalence of blood disorders, favorable government programs,
and high level of awareness among healthcare professionals and patients for hemoglobinopathies-related
genetic testing are factors attributing to the major share of this market.
· Asia Pacific market is expected to witness
lucrative growth over the forecast period with a CAGR of over 10% owing to the
presence of high unmet clinical needs, improving healthcare infrastructure, and
rising economic levels. Moreover, introduction of low-cost diagnostic
alternatives will enhance adoption rates for hemoglobinopathies diagnostics
market.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
hemoglobinopathies market on the basis of type, diagnostics, and therapeutics:
Global Hemoglobinopathies Therapy Outlook
(Revenue, USD Million), 2012 – 2022
·
Thalassemia
·
Sickle cell disease
·
Hemoglobin variants diseases
Global Hemoglobinopathies Diagnosis Outlook
(Revenue, USD Million), 2012 – 2022
·
Thalassemia
·
Sickle cell disease
·
Hemoglobin variants diseases
Hemoglobinopathies Regional Outlook
(Revenue, USD Million), 2012 – 2022
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
MEA
Access Press Release of
Hemoglobinopathies Market@ www.grandviewresearch.com/press-release/global-hemoglobinopathies-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
